NASHVILLE, TN--(Marketwire - October 22, 2010) - International Merchant Advisors, Inc. (
This signals the end of Seth Maling's tenure as CEO and he will return to his former role as Director of Business Development. He said he "couldn't be more pleased with the board's choice" in a company statement.
Gordon Getz began his career as a pharmaceutical research biologist with Sterling Winthrop Research Institute in Renssalaer, NY and also has over 35 years of experience in sales and marketing in the pharmaceutical and specialty medical device sector of the healthcare industry including Pfizer Pharmaceuticals and Bristol Laboratories. Commenting on his appointment, Mr. Getz said, "I am extremely honored to take on the role of CEO of International Merchant Advisors. I look forward to working closely with other executives within the medical industry particularly the medical marijuana sector. I will strive to pick-up the pieces and move forward with new ideas and leadership to grow the Company and increase shareholder value."
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report.